

Best of UEG Week - IBD

Tim Raine

Podcast Episode

IBD

November 22, 2023

This episode reviews key IBD research from UEG Week Copenhagen, focusing on head-to-head biologic trials, subcutaneous infliximab switching, and pre-symptomatic disease identification.

KEY POINTS

- The SEQUENCE trial compared risankizumab with ustekinumab in over 500 Crohn's disease patients previously treated with anti-TNF therapy, showing risankizumab achieved approximately double the endoscopic remission rate at week 48 (30-32% versus 16%) with significant advantages across all secondary endpoints.
- Multiple studies presented support switching patients from intravenous to subcutaneous infliximab as safe and effective across a range of dosing regimens, with possible superiority, though patients on 10mg/kg every four weeks IV may be challenging to switch.
- Phase 2 data for the anti-TROMBA drug PRO-023 showed approximately 30% placebo-adjusted delta for clinical remission in biologic-naive patients and strong efficacy in bio-exposed patients, notably with a companion diagnostic biomarker to predict response.
- Joanna Torres presented work on identifying IBD in pre-symptomatic stages through large cohort studies, demonstrating that serological, microbiological, and other predictors appear years before diagnosis in at-risk individuals, raising potential for early lifestyle or microbial interventions.
- This episode will be most useful for gastroenterologists managing IBD patients and those interested in emerging biologic positioning and pre-diagnostic disease research.

VIEW THIS CONTENT ON GUTFLIX

<https://gutflix.eu/search/d/c87da0ca-2e20-11ef-b854-0242ac140004>



AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.